



**PRESS RELEASE
FOR IMMEDIATE RELEASE**

Ovensa Collaborates with Takeda to Deliver an Antibody to the Brain

Aurora, Ontario, March 21st, 2019 – Ovensa Inc. (“Ovensa”) is pleased to announce that it has entered into a collaboration agreement with Takeda Pharmaceutical Company Limited (“Takeda”) to evaluate Ovensa’s proprietary nanomedicine platform called TRIOZAN™ for the delivery of an antibody to the brain and evaluate its performance in a CNS disease model.

"We are extremely proud of this new partnership, which demonstrates a great deal of confidence in our unique delivery system which helps therapeutic molecules better cross the human body’s various barriers such as the skin, the mucous membranes or the blood-brain barrier and reach their target. Takeda is the largest pharmaceutical company in Japan and is present in more than 70 countries. We are starting this collaboration with enthusiasm and hope that this partnership will accelerate the discussions we have with some 30 other companies," says Ovensa’s President and CEO, Mr. Stéphane Gagné.

Ovensa offers a platform allowing for the development of custom nanomedicines based on trimethylchitosan - a biopolymer derived from crustacean chitosan. Whether it is for reducing the side effects of chemotherapy, changing the expression of a gene that does not function normally or eliciting an optimal immune response of an antibody in the brain, the platform allows high engineering flexibility where nanomedicines are specifically designed to cross barriers and optimize tissue or cell targeting based on the disease.

Although Ovensa’s platform research focuses on complex diseases for which there are few available treatments such as brain cancer and Alzheimer's Disease, it also applies to other therapeutic areas such as metabolic diseases, animal health or antibiotic resistance. Also using its patented TRIOZAN™ platform, Ovensa is conducting trials with its collaborators to develop new custom nanomedicines using cannabinoids such as cannabidiol (CBD) to treat various diseases including certain cancers, diseases of the central nervous system and pain.

Terms of the agreement with Takeda have not been disclosed.



Ovensa is a preclinical stage company fighting inherent therapeutic resistance in complex diseases by generating advanced nanotherapeutics using its proprietary TRIOZAN™ Delivery Platform. The company focuses on advancing its lead candidate in glioblastoma as well as generating novel nanotherapeutic candidates in collaboration with pharmaceutical companies for applications in CNS and immuno-oncology.

Information

Stéphane Gagné
President & CEO, Ovensa Inc.
905-726-9933
sgagne@ovensa.com